Pulse Biosciences Stock Performance
| PLSE Stock | USD 13.55 0.77 5.38% |
The company holds a Beta of 1.36, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Pulse Biosciences will likely underperform. At this point, Pulse Biosciences has a negative expected return of -0.32%. Please make sure to check Pulse Biosciences' potential upside, as well as the relationship between the day median price and relative strength index , to decide if Pulse Biosciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Pulse Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in March 2026. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return (5.38) | Five Day Return (6.49) | Year To Date Return 1.19 | Ten Year Return 224.94 | All Time Return 224.94 |
1 | Pulse Biosciences, Inc. Q3 2025 Earnings Call Transcript | 11/07/2025 |
2 | Is Pulse Biosciences Inc. stock a buy before product launches - Trade Volume Report Weekly High Potential Stock Alerts - Newser | 12/02/2025 |
3 | Acquisition by Zanganeh Mahkam of 30000 shares of Pulse Biosciences at 16.16 subject to Rule 16b-3 | 12/05/2025 |
4 | Pulse Biosciences to evaluate PFA in treating thyroid cancer | 12/09/2025 |
5 | Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635 | 12/19/2025 |
6 | Why Pulse Biosciences Is Up 8.0 percent After FDA Clears Pivotal Atrial Fibrillation Trial | 12/22/2025 |
7 | Pulse Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference - Yahoo Finance Singapore | 12/29/2025 |
8 | Will Pulse Biosciences Inc. stock outperform value peers - Earnings Overview Summary Growth Focused Entry Reports - ulpravda.ru | 01/08/2026 |
9 | Analyst Calls Is Pulse Biosciences Inc stock recession proof - 2025 Earnings Impact Daily Profit Focused Screening - moha.gov.vn | 01/13/2026 |
10 | Pulse Biosciences Trading Down 1.4 percent Whats Next | 01/16/2026 |
11 | Technical Reactions to PLSE Trends in Macro Strategies - Stock Traders Daily | 01/28/2026 |
| Begin Period Cash Flow | 44.4 M | |
| Total Cashflows From Investing Activities | -125 K |
Pulse Biosciences Relative Risk vs. Return Landscape
If you would invest 1,693 in Pulse Biosciences on October 31, 2025 and sell it today you would lose (338.00) from holding Pulse Biosciences or give up 19.96% of portfolio value over 90 days. Pulse Biosciences is currently does not generate positive expected returns and assumes 2.9341% risk (volatility on return distribution) over the 90 days horizon. In different words, 26% of stocks are less volatile than Pulse, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Pulse Biosciences Target Price Odds to finish over Current Price
The tendency of Pulse Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 13.55 | 90 days | 13.55 | about 79.73 |
Based on a normal probability distribution, the odds of Pulse Biosciences to move above the current price in 90 days from now is about 79.73 (This Pulse Biosciences probability density function shows the probability of Pulse Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.36 indicating as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Pulse Biosciences will likely underperform. Additionally Pulse Biosciences has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Pulse Biosciences Price Density |
| Price |
Predictive Modules for Pulse Biosciences
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Pulse Biosciences. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Pulse Biosciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Pulse Biosciences Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Pulse Biosciences is not an exception. The market had few large corrections towards the Pulse Biosciences' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Pulse Biosciences, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Pulse Biosciences within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.44 | |
β | Beta against Dow Jones | 1.36 | |
σ | Overall volatility | 1.25 | |
Ir | Information ratio | -0.14 |
Pulse Biosciences Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Pulse Biosciences for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Pulse Biosciences can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Pulse Biosciences generated a negative expected return over the last 90 days | |
| Net Loss for the year was (53.59 M) with loss before overhead, payroll, taxes, and interest of (193 K). | |
| Pulse Biosciences currently holds about 14.8 M in cash with (36.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.4. | |
| Pulse Biosciences has a poor financial position based on the latest SEC disclosures | |
| Roughly 74.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Technical Reactions to PLSE Trends in Macro Strategies - Stock Traders Daily |
Pulse Biosciences Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Pulse Stock often depends not only on the future outlook of the current and potential Pulse Biosciences' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Pulse Biosciences' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 58.4 M | |
| Cash And Short Term Investments | 118 M |
Pulse Biosciences Fundamentals Growth
Pulse Stock prices reflect investors' perceptions of the future prospects and financial health of Pulse Biosciences, and Pulse Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pulse Stock performance.
| Return On Equity | -0.87 | ||||
| Return On Asset | -0.49 | ||||
| Operating Margin | (236.83) % | ||||
| Current Valuation | 883.11 M | ||||
| Shares Outstanding | 67.77 M | ||||
| Price To Earning | (22.54) X | ||||
| Price To Book | 10.47 X | ||||
| Price To Sales | 11,284 X | ||||
| Gross Profit | (193 K) | ||||
| EBITDA | (55.08 M) | ||||
| Net Income | (53.59 M) | ||||
| Cash And Equivalents | 14.8 M | ||||
| Cash Per Share | 0.40 X | ||||
| Total Debt | 8.9 M | ||||
| Debt To Equity | 0.45 % | ||||
| Current Ratio | 3.14 X | ||||
| Book Value Per Share | 1.37 X | ||||
| Cash Flow From Operations | (36.34 M) | ||||
| Earnings Per Share | (1.14) X | ||||
| Market Capitalization | 958.23 M | ||||
| Total Asset | 132.46 M | ||||
| Retained Earnings | (390.5 M) | ||||
| Working Capital | 109.39 M | ||||
| Current Asset | 4 M | ||||
| Current Liabilities | 660 K | ||||
About Pulse Biosciences Performance
By analyzing Pulse Biosciences' fundamental ratios, stakeholders can gain valuable insights into Pulse Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Pulse Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Pulse Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 972.15 | 864.13 | |
| Return On Tangible Assets | (0.48) | (0.50) | |
| Return On Capital Employed | (0.53) | (0.55) | |
| Return On Assets | (0.47) | (0.49) | |
| Return On Equity | (0.42) | (0.40) |
Things to note about Pulse Biosciences performance evaluation
Checking the ongoing alerts about Pulse Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Pulse Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pulse Biosciences generated a negative expected return over the last 90 days | |
| Net Loss for the year was (53.59 M) with loss before overhead, payroll, taxes, and interest of (193 K). | |
| Pulse Biosciences currently holds about 14.8 M in cash with (36.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.4. | |
| Pulse Biosciences has a poor financial position based on the latest SEC disclosures | |
| Roughly 74.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Technical Reactions to PLSE Trends in Macro Strategies - Stock Traders Daily |
- Analyzing Pulse Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pulse Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Pulse Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pulse Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pulse Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pulse Biosciences' stock. These opinions can provide insight into Pulse Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Pulse Stock analysis
When running Pulse Biosciences' price analysis, check to measure Pulse Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pulse Biosciences is operating at the current time. Most of Pulse Biosciences' value examination focuses on studying past and present price action to predict the probability of Pulse Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pulse Biosciences' price. Additionally, you may evaluate how the addition of Pulse Biosciences to your portfolios can decrease your overall portfolio volatility.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |